Role of glypican-1 in regulating multiple cellular signaling pathways

被引:40
作者
Pan, Jiajia [1 ,2 ]
Ho, Mitchell [1 ]
机构
[1] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China
来源
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY | 2021年 / 321卷 / 05期
关键词
cancer; glypican-1; signaling pathways; therapeutic target; SULFATE PROTEOGLYCAN GLYPICAN-1; SINGLE-DOMAIN ANTIBODY; TGF-BETA; TARGETING GLYPICAN-1; COMMISSURAL AXONS; CANONICAL WNT; CORE PROTEIN; MOUSE MODEL; CANCER; EXPRESSION;
D O I
10.1152/ajpcell.00290.2021
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Glypican-1 (GPC1) is one of the six glypican family members in humans. It is composed of a core protein with three heparan sulfate chains and attached to the cell membrane by a glycosyl-phosphatidylinositol anchor. GPC1 modulates various signaling pathways including fibroblast growth factors (FGF), vascular endothelial growth factor-A (VEGF-A), transforming growth factor-beta (TGF-beta), Wnt Hedgehog (Hh), and bone morphogenic protein (BMP) through specific interactions with pathway ligands and receptors. The impact of these interactions on signaling pathways, activating or inhibitory, is dependent upon specific GPC1 domain interaction with pathway components, as well as cell surface context. In this review, we summarize the current understanding of the structure of GPC1, as well as its role in regulating multiple signaling pathways. We focus on the functions of GPC1 in cancer cells and how new insights into these signaling processes can inform its translational potential as a therapeutic target in cancer.
引用
收藏
页码:C846 / C858
页数:13
相关论文
共 99 条
  • [21] Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis
    Gao, Wei
    Tang, Zhewei
    Zhang, Yi-Fan
    Feng, Mingqian
    Qian, Min
    Dimitrov, Dimiter S.
    Ho, Mitchell
    [J]. NATURE COMMUNICATIONS, 2015, 6
  • [22] Inactivation of Wnt Signaling by a Human Antibody That Recognizes the Heparan Sulfate Chains of Glypican-3 for Liver Cancer Therapy
    Gao, Wei
    Kim, Heungnam
    Feng, Mingqian
    Phung, Yen
    Xavier, Charles P.
    Rubin, Jeffrey S.
    Ho, Mitchell
    [J]. HEPATOLOGY, 2014, 60 (02) : 576 - 587
  • [23] Gao Wei, 2011, Cancer Rep, V1, P14
  • [24] Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165
    Gengrinovitch, S
    Berman, B
    David, G
    Witte, L
    Neufeld, G
    Ron, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (16) : 10816 - 10822
  • [25] Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
    Hara, Hisashi
    Takahashi, Tsuyoshi
    Serada, Satoshi
    Fujimoto, Minoru
    Ohkawara, Tomoharu
    Nakatsuka, Rie
    Harada, Emi
    Nishigaki, Takahiko
    Takahashi, Yusuke
    Nojima, Satoshi
    Miyazaki, Yasuhiro
    Makino, Tomoki
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Miyata, Hiroshi
    Nakajima, Kiyokazu
    Takiguchi, Shuji
    Morii, Eiichi
    Mori, Masaki
    Doki, Yuichiro
    Naka, Tetsuji
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (01) : 66 - 75
  • [26] Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
    Harada, Emi
    Serada, Satoshi
    Fujimoto, Minoru
    Takahashi, Yusuke
    Takahashi, Tsuyoshi
    Hara, Hisashi
    Nakatsuka, Rie
    Sugase, Takahito
    Nishigaki, Takahiko
    Saito, Yurina
    Hiramatsu, Kosuke
    Nojima, Satoshi
    Mitsuo, Risa
    Ohkawara, Tomoharu
    Morii, Eiichi
    Mori, Masaki
    Doki, Yuichiro
    Kaneda, Yasufumi
    Naka, Tetsuji
    [J]. ONCOTARGET, 2017, 8 (15) : 24741 - 24752
  • [27] Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma
    Hippo, Y
    Watanabe, K
    Watanabe, A
    Midorikawa, Y
    Yamamoto, S
    Ihara, S
    Tokita, S
    Iwanari, H
    Ito, Y
    Nakano, K
    Nezu, J
    Tsunoda, H
    Yoshino, T
    Ohizumi, I
    Tsuchiya, M
    Ohnishi, S
    Makuuchi, M
    Hamakubo, T
    Kodama, T
    Aburatani, H
    [J]. CANCER RESEARCH, 2004, 64 (07) : 2418 - 2423
  • [28] Advances in Liver Cancer Antibody Therapies A Focus on Glypican-3 and Mesothelin
    Ho, Mitchell
    [J]. BIODRUGS, 2011, 25 (05) : 275 - 284
  • [29] Glypican-1 facilitates prion conversion in lipid rafts
    Hooper, Nigel M.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2011, 116 (05) : 721 - 725
  • [30] α3 Chains of type V collagen regulate breast tumour growth via glypican-1
    Huang, Guorui
    Ge, Gaoxiang
    Izzi, Valerio
    Greenspan, Daniel S.
    [J]. NATURE COMMUNICATIONS, 2017, 8